Bank of New York Mellon Corp Has $1.52 Million Stake in Merus (NASDAQ:MRUS)

Bank of New York Mellon Corp decreased its position in shares of Merus (NASDAQ:MRUS) by 3.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,038 shares of the biotechnology company’s stock after selling 1,248 shares during the quarter. Bank of New York Mellon Corp’s holdings in Merus were worth $1,515,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Avior Wealth Management LLC bought a new position in Merus during the 4th quarter worth approximately $76,000. MML Investors Services LLC bought a new position in Merus during the 3rd quarter worth approximately $206,000. Gordian Capital Singapore Pte Ltd boosted its stake in Merus by 10.4% during the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 470 shares during the last quarter. HighTower Advisors LLC bought a new position in Merus during the 3rd quarter worth approximately $358,000. Finally, Harbour Capital Advisors LLC bought a new position in Merus during the 4th quarter worth approximately $360,000. Institutional investors own 96.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MRUS. Citigroup lifted their price objective on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Bank of America reduced their price objective on shares of Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. William Blair reaffirmed an “outperform” rating on shares of Merus in a research note on Friday, February 28th. Wells Fargo & Company began coverage on shares of Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target on the stock. Finally, Piper Sandler began coverage on shares of Merus in a research note on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target on the stock. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $85.31.

Merus Stock Down 2.2 %

Shares of MRUS stock opened at $47.24 on Friday. The company’s fifty day simple moving average is $43.34 and its 200-day simple moving average is $46.21. The firm has a market cap of $3.26 billion, a PE ratio of -11.96 and a beta of 1.15. Merus has a 12 month low of $37.77 and a 12 month high of $61.61.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.48. The business had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. On average, equities analysts predict that Merus will post -3.85 earnings per share for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.